# The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema

> **NCT06075147** · — · ACTIVE_NOT_RECRUITING · sponsor: **Bayer** · enrollment: 2500 (estimated)

## Conditions studied

- Visual Impairment
- Neovascular Age-related Macular Degeneration (nAMD)
- Diabetic Macula Edema (DME)

## Interventions

- **DRUG:** Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)

## Key facts

- **NCT ID:** NCT06075147
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-15
- **Primary completion:** 2027-09-30
- **Final completion:** 2028-01-31
- **Target enrollment:** 2500 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06075147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06075147, "The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06075147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*